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Background: Similarity of pharmacokinetics of intranasal ketorolac to the intravenous form and other advantages 
have promoted its application. This study compared the analgesic effects of intravenous and intranasal ketorolac in 
patients undergoing mandibular fracture surgery. 
Material and Methods: In this clinical trial study, Sixty-four patients with unilateral mandibular fracture were divi-
ded randomly into two groups. In group 1, 30 mg of intravenous (IV) ketorolac was injected every 8 hours and in 
group 2, intranasal (IN) ketorolac spray was used as a 100-µL puff in each nostril (31.5 mg) every 6 hours. After 
each patient regained consciousness, pain intensity was measured based on visual analogue scale for 48 hours. Fi-
nally, the total dose of the opioid analgesic agent (pethidine) and the time for the first request for an analgesic agent 
were recorded for each patient, and their means were compared in each group with proper statistical tests.
Results: Mean pain intensity of patients at baseline was significantly higher than that at other intervals and then, 
it decreased significantly (P<0.001). Furthermore, 2, 4, 6 and 8 hours after surgery, mean pain intensity in the IN 
group was significantly lower than that in the IV group (P<0.05). In the IN group, dose of antinociceptive medicine 
was slightly higher and the time to request it was shorter than the other group, but it was not statistically significant 
(P>0.05). 
Conclusions: Application of intranasal ketorolac spray decreased pain after mandibular fracture surgery, especially 
at 8-hour interval after surgery, decreasing the need for opioids.
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Introduction
Pain which is an unpleasant feeling caused by destruc-
tion of a tissue disrupts the daily life even in its lowest 
rate. One of the most agonizing pains for patients is 
postoperative pain which is caused by inflammation and 
release of chemical mediators (1,2). Lack of pain during 
the postoperative period is one of the necessary factors 
for discharging patients from the hospital (3,4). 
Antinociceptive drugs typically consist of opioids which 
might have side effects like postoperative ileus, urinary 
retention, itching, dizziness, dependence, tolerance, ad-
diction, vomiting and nausea. Based on the report of the 
Commission of Healthcare Accreditation Organization 
(CAHO), use of opioids in the postoperative period 
leads to patient dissatisfaction. On the other hand, use 
of partial agonists like tramadol has side effects like 
nausea, vomiting and ileus (3-5). Therefore, many re-
searchers and clinicians are seeking non-opioid anti-
nociceptive drugs. Medicines like NSAID and NMDA 
(N-Methyl-D-Aspartate) agonists, α2 agonists, calcium 
channel blockers, local infiltration or peripheral neural 
block with anesthetics, and non-pharmaceutical agents 
like transcutaneous electrical nerve stimulation (TENS) 
have been used, each with their own strengths, weaknes-
ses and side effects (5). 
Currently, use of NSAIDs, in combination with opioids 
or alone, is a part of multimodal antinociceptive treat-
ments in controlling mild-to-moderate pains such as 
pain after maxillofacial, orthopedic and outpatient sur-
geries (2,6,7). 
Ketorolac is an injectable NSAID drug with antinoci-
ceptive and antiinflammatory properties. This drug be-
longs to heterocyclic acetic acid family and has high 
antinociceptive effects and moderate antiinflammatory 
properties. The effect of this medicine occurs through 
blocking the formation of prostaglandins by blocking 
cyclooxygenase enzyme. Ketorolac, like other NSAIDs, 
is a non-selective COX inhibitor. Ketorolac is used to 
manage short-term moderate-to-severe postoperative 
pains. Maximum allowed time to use this medicine in 
oral form is 5 days, with 2 days for the injection form 
(intravenous or intramuscular) (1,8-10). 
Intranasal spray (31.5 mg every 6–8 hours for 5 days) 
is another form of ketorolac, which has been introdu-
ced in recent years. Pharmacokinetics and half-life of 
intranasal spray are similar to the intravenous form. Its 
application have been promoted by its other advantages 
like ease of use, lack of pain during its intravenous or in-
tramuscular injection and its use in patients with lockout 
oral feeding (11). 
Previous studies have shown that prescription of intrana-
sal ketorolac reduces pain in patients undergoing impac-
ted tooth surgery (12), dental implants surgery (13) and 
orthopedic and abdominal surgeries (14). Furthermore, 
in a study, intranasal ketorolac in the first hour after 
surgery in 300 candidates for hysterectomy and hip re-
placement reduced pain compared to the control group. 
In addition, patients received less opioids (11). He et 
al. (15) in a systematic review in 2012, reported that 
using intranasal ketorolac spray can significantly reduce 
postoperative pain of patients. Yet, no comprehensive 
study is available on the application of intravenous and 
intranasal ketorolac in patients undergoing maxillofacial 
fracture surgeries. In most above-mentioned studies, the 
application of intranasal ketorolac as an antinociceptive 
agent has been confirmed against placebo. Therefore, 
this study aimed to compare the antinociceptive effects 
of intravenous and intranasal ketorolac in mandible frac-
ture patients. If the antinociceptive effects of intranasal 
ketorolac are equal or better than its injected form, it can 
replace injected form due to its ease of use.
 
Material and Methods
In this parallel randomized clinical trial, conducted from 
March to September 2018 in Imam Reza Hospital in Ta-
briz, 64 patients, with unilateral fracture in the body, an-
gle and parasymphysis of the mandible with indication 
for open reduction with intraoral method, were selected 
by simple random sampling and included in the study 
after obtaining informed consent. 
-Determining the sample size 
The results of a study by Alexander et al(16) were used 
to determine the sample size, in which the mean pain 
intensities in the intranasal ketorolac and control groups 
were 64.5±1.9 and 63.1±1.5, respectively. By consi-
dering α=0.05 and 80% study power, 25 samples were 
selected for each group; however, the sample size in-
creased up to 25% in order to increase the accuracy of 
the study. Therefore, 32 samples were estimated for each 
group and totally, 64 subjects were selected. 
-Inclusion criteria 
1) Consent and intention to participate in the study
2) Patients with unilateral maxillofacial fracture in the 
body, angle and parasymphysis, with fracture occurring 
not more than two weeks ago
3) Patients in an age range of 20–60 years (due to higher 
incidence of maxillofacial traumas in this age range) 
(17)
4) ASA I (healthy patients) and ASA II patients (patients 
with mild systemic problems and without functional li-
mitations (18)
5) A VAS of ≥4 immediately after regaining conscious-
ness (moderate to severe pain) (13)
-Exclusion criteria 
1) Surgery lasting for >2 hours (due to complicated ope-
ration)
2) Drug abuse by the patient 
3) Psychopathic patients (all the patients taking psycho-
pathic medicines were excluded due to palliative effects 
of these medications)
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4) Drug allergy 
5) Systemic diseases that might be exacerbated due to 
drug side effects
6) A history of seizures (due to anticonvulsive drug 
effects)
7) More than one incision site 
8) Use of more than two plates
9) Edentulous patients (due to the difference in surgery 
procedure like circum wire)
-Description of study groups 
The patients were divided randomly into two groups by a 
person not aware of the study objectives by using Rand-
List software. In group 1, a 30-mg dose of intravenous 
ketorolac every 8 hours was prescribed and in group 2, 
a 15.75-mg dose of intranasal ketorolac (SPRIX, Egalet 
US Inc, USA) was prescribed as a 100-µL puff in each 
nostril (31.5 mg) every 6 hours.
-Evaluation of the study outcomes 
The primary outcome of this study was the relief of 
postoperative pain. After regaining consciousness, the 
pain intensity was measured based on VAS for 48 hours 
at baseline and at 2-, 4-, 6-, 12-, 24-, 36- and 48-hour 
intervals. For this purpose, the patients were asked to 
express their pain intensity as a number from 0 (without 
pain) to 10 (severe and unbearable pain). Mean pain sco-
re for each patient in the study groups and at different 
time intervals were recorded and compared. The physi-
cian prescribed pethidine (25 mg) intravenously by the 
request of patient (PRN). Finally, total opioid dose (pe-
thidine) was recorded for each patient in mg during the 
first 48 hours and the time of request for antinociceptive 
in minutes and the means of the groups were compared.
Before initiating the study, each nurse was given the ne-
cessary instructions by the researcher about how to fill 
the checklist. The study process and pain scoring system 
were explained to the patients. All the patients comple-
ted the study and none left the study or was excluded. 
In this study, the surgeon and nurses in the ward, who 
recorded the prescribed doses of opioids and the first re-
quest for antinociceptives by the patient, were blinded to 
the study procedures. All the surgeries were carried out 
by a maxillofacial surgeon. 
All the patients underwent the general diagnostic pro-
cedures and treatment planning and none was deprived 
of care. All the ethical aspects of this study were appro-
ved by the Ethics Committee of Tabriz University of 
Medical Sciences (IR.TBZMED.REC.1396.1270). The 
study was registered in Iranian Clinical Trials Registra-
tion Center under the code IRCT2015062802295NB. At 
the beginning of the study, informed consent forms were 
signed by the subjects after proper explanations were 
provided by the researcher and explained to the patients 
in order to solve the problem of illiterate patients.
-Analysis of data 
Data were analyzed with descriptive statistical methods 
(frequencies, percentages, means and standard devia-
tions), one-way ANOVA and repeated measures ANO-
VA using SPSS 19. Data normality was evaluated by 
Kolmogorov-Smirnov test. Statistical significance was 
set at P<0.05. 
Results
In this study, 64 patients (48 men and 16 women) were 
evaluated with a mean age of 14.7±33.7 years (Table 1) 
(Fig. 1). 
The results of chi-squared test in terms of the gender of 
participants and the fracture site, and independent t-test 
in terms of mean age of patients showed no significant 
differences between the study groups (P>0.05). In other 
words, patients in both groups were the same regarding 
mean age and fracture type. 
Table 2 indicates the mean pain intensity of patients in 
the study groups at different time intervals. As seen, 
pain intensity in patients immediately after regaining 
consciousness was highest, decreasing gradually in 48 
hours. Repeated-measures ANOVA showed that this was 
statistically significant (P<0.001). Sidak test was used 
for pairwise comparisons of different time intervals and 
mean pain intensity of patients. The results are presented 
in Table 3. 
Based on Sidak test results, mean pain intensity of pa-
tients immediately after regaining consciousness was 
significantly higher than the means at other intervals and 
it was at the highest level (P<0.001).
Injection group Spray group Total P-value
Gender Female 7 (21.9%) 9 (28.1%) 16 (25%) 0.564
Male 25 (78.1%) 23 (71.9%) 48 (75%)
Fracture site Parasymphysis 12 (37.5%) 6 (18.8%) 18 (28.1%) 0.249
Body 13 (40.6%) 17 (53.1%) 30 (64.9%)
Angle 7 (21.9%) 9 (28.1%) 16 (25%)
Mean age ± standard deviation 33.06±13.8 34.34±15.82 33.7±14.7 0.731
Table 1: Mean ages and frequencies (percentages) in terms of gender and fracture site of the patients.
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Fig. 1: The CONSORT Flow diagram of study patients.
Patients’ pain intensity 2 hours after receiving the first 
antinociceptive dose was the highest compared to 4-, 
6-, 8-, 12-, 24-, 36- and 48-hour intervals (P<0.001). 
This process continued 12 hours after prescribing drug 
such that at each time interval of the study, pain intensi-
ty was higher compared to the following time intervals 
(P<0.001). In comparison of mean pain intensity in pa-
tients at 24-, 36- and 48-hour intervals after receiving 
drug, although slight clinical reduction in pain intensity 
of patients was observed, this decrease was not signifi-
cant statistically (P>0.05). Therefore, mean pain intensi-
ty of patients 24 hours after receiving medicine up to 48 
hours later was the same and in a very low level. 
Independent-samples t-test was used to study the effect 
of antinociceptive drug on mean pain intensity at each 
study interval. The results of this test showed that 2, 4, 
6 and 8 hours after surgery, mean pain intensity in the 
ketorolac spray group was significantly lower than that 
in the injection group. In addition, mean 48-hour mean 
pain intensity in the ketorolac spray group was signifi-
cantly lower than that in the other group (P<0.05). In 
contrast, immediately after regaining consciousness and 
12, 24, 36 and 48 hours after surgery, means of pain in-
tensity were not significantly different between the two 
groups (P>0.05). 
The prescribed dose of antinociceptive agent during the 
48-hour period after surgery and the first request for an-
tinociceptive were recorded separately for each group 
(Table 4). The results indicated that in the spray group, 
the dose of the antinociceptive agent was slightly higher 
and the time to request the antinociceptive agent was 
slightly shorter than other group. However, t-test for in-
dependent groups showed that this was not statistically 
significant (P>0.05). 
Discussion 
Use of opioid antinociceptives results in patients’ dissatis-
faction due to their various side effects. Therefore, clini-
cians are not much interested in using them (3-5). On the 
contrary, there is more willingness to apply effective com-
pounds to the central and peripheral nervous systems and 
use multimodal methods to reduce pain severity (19,20).




























































































































































































































































































































NSAID drugs have been reported to be effective as a part 
of antinociceptive multimodal treatments in controlling 
mild to moderate pains, like maxillofacial postoperative 
pain, small orthopedic surgeries and outpatient surgeries 
(6,7). Ketorolac is an NSAID drug and belongs to hete-
rocyclic acetic acid family with high antinociceptive and 
moderate antiinflammatory properties (9,10).
The results of this study, which was designed and im-
plemented to compare palliative effect of intravenous 
and intranasal ketorolac in mandible fracture surgeries, 
indicated that mean pain intensity of patients in both 
groups immediately after regaining consciousness was 
highest but it significantly decreased in 48 hours. Pa-
tients in the ketorolac spray group exhibited lower pain 
during the first 2 to 8 hours after regaining conscious-
ness compared to the other group. Since patients in the 
intranasal ketorolac group received spray every 6 hours 
and every 8 hours in the injection group, in the first 
8 hours, two doses (63 mg) and 1 dose (30 mg) were 
prescribed in spray and injection groups, respectively. 
Therefore, receiving a higher dose in the spray group 
can be effective in the lower pain intensity of patients 
in this group. Different studies indicated that pharma-
cokinetics and half-life of intranasal ketorolac (5.24 
hours) is similar to its intravenous form (5–6 hours), 
explaining its considerable antinociceptive effects of 
intranasal ketorolac (12,21).  
In this study, 12 to 48 hours after surgery, pain intensity 
was the same in both groups but its intensity decreased 
compared to the first 8 hours. The results also showed 
that the mean time of first opioid drug request and its 
dose were the same in both groups. 
Brown et al. (11) studied 300 candidates of hysterec-
tomy and hip replacement patients who needed at least 
5 days of hospitalization. In one group, 100 µL of in-
tranasal ketorolac was prescribed in each nostril every 
8 hours in 5 days, and placebo (in the same dose and as 
intranasal spray) was used in the other group. Patients 
received morphine sulfate after surgery and this drug 
was injected upon their request. The results indicated 
that in the first hour after surgery, intranasal ketorolac 
significantly reduced the pain intensity. They concluded 
that rapid pain relief property of intranasal ketorolac can 
be useful in managing moderate to severe postoperati-
ve pain. In addition, patients in the intranasal ketorolac 
group received less opioids. The results of the study abo-
ve are consistent with those of the present study, which 
indicated that intranasal ketorolac in early hours after 
surgery can significantly reduce the pain intensity wi-
thout increasing the dose of opioid agents. Of course, in 
this study, patients in both groups asked for opioids in 
the first 70 minutes after regaining consciousness and re-
ceiving ketorolac injection or spray. However, in a study 
by Brown et al. (11), patients did not ask for opioids 
at least three hours after surgery. These values are very 
lower than 6–8-hour interval which has been known as 
the mean painless time caused by each ketorolac dose 
(22). This difference in the results can be due to the di-
fference in surgeries and the injury intensity. It is also 
possible that the reason for early request of opioids was 
the fact that the patients expected free access to opioids. 
He et al. (15) reported in a systematic review that using 
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Evaluation time (I) Evaluation time (J) Mean difference (I-J) P-value
Immediately after awakening 2 hours later 1.328* <.001
4 hours later 2.500* <.001
6 hours later 3.359* <.001
8 hours later 3.953* <.001
12 hours later 4.500* <.001
24 hours later 5.031* <.001
36 hours later 5.078* <.001
48 hours later 5.094* <.001
2 hours later 4 hours later 1.172* <.001
6 hours later 2.031* <.001
8 hours later 2.625* <.001
12 hours later 3.172* <.001
24 hours later 3.703* <.001
36 hours later 3.750* <.001
48 hours later 3.766* <.001
4 hours later 6 hours later 0.859* <.001
8 hours later 1.453* <.001
12 hours later 2.000* <.001
24 hours later 2.531* <.001
36 hours later 2.578* <.001
48 hours later 2.594* <.001
6 hours later 8 hours later 0.594* <.001
12 hours later 1.141* <.001
24 hours later 1.672* <.001
36 hours later 1.719* <.001
48 hours later 1.734* <.001
8 hours later 12 hours later 0.547* <.001
24 hours later 1.078* <.001
36 hours later 1.125* <.001
48 hours later 1.141* <.001
12 hours later 24 hours later 0.531* <.001
36 hours later 0.578* <.001
48 hours later 0.594* <.001
24 hours later 36 hours later 0.047 0.959
48 hours later 0.063 0.806
36 hours later 48 hours later 0.016 1.000
Table 3: Sidak test results.
intranasal ketorolac reduces the postoperative pain sig-
nificantly.
Singla et al. (23) showed that prescribing intranasal ke-
torolac with a 31.5-mg dose 6 times a day in the first 48 
hours and 4 times a day for the next 2 to 5 days, reduces 
the pain and discomfort of patients undergoing abdomi-
nal surgery and the need for opioids after surgery. 
Grant et al. (12) evaluated 80 impacted tooth surgery 
candidates. Immediately after surgery, 100 µL of intra-
nasal ketorolac was used in each nostril of a group (31.5 
mg) and placebo in the other group. Pain intensity was 
measured 20, 40, 60 and 90 minutes, and 2, 3, 4, 5, 6, 
7, and 8 hours after surgery based on VAS. The results 
showed that in the first 20 minutes after surgery, the anti-
nociceptive effects of ketorolac were high and continued 
for the next 6–8 hours.
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Injection 0 50 13.28±5.53 0.244
Spray 0 50 14.8±4.8
Time to request the 
first antinociceptive 
dose
Injection 15 90 72.2±3.7 0.899
Spray 10 80 70.06±5.01
Table 4: Mean prescribed dose of antinociceptive drug (mg) and the time of first antinociceptive request in different study groups.
Bockow et al. (13) showed that prescribing 31.5 mg of 
intranasal ketorolac reduced pain in the first 20 minutes 
after implant surgery and its effects lasted for 6 hours.
These results are consistent with our results that pres-
cribing ketorolac, especially in the intranasal form, 
had antinociceptive effects 6 to 8 hours after surgery. 
Of course, in all these studies, the effect of placebo was 
compared with ketorolac spray. In this study, for the first 
time, the effects of ketorolac injection and spray were 
compared. 
Previous studies reported side effects for intranasal ke-
torolac. Approximately 24% of patients who used intra-
nasal ketorolac exhibited transient nasal passage which 
was removed a few minutes after consuming the drug 
(11). Headache and burning nasal mucus were reported 
after using intranasal ketorolac (12,13). In the present 
study, patients had no problem, and no case of nose in-
flammation and other effects were reported. 
The use of intranasal ketorolac in patients with in-
ter-maxillary fixation and limited oral antinociceptive 
agents can be useful. The similarity of pharmacokinetics 
and half-life of intranasal spray in its injected form and 
other advantages, like ease of use and not imposing in-
travenous or intramuscular injection pain, have increa-
sed the interest in its use. Of course, ketorolac spray is 
recommended only for 5 days because it has some side 
effects (11). 
-Limitations and suggestions 
There was no control group in this study. Therefore, 
the accurate and comprehensive comparison of opioid 
dose and painless time based on antinociceptive medici-
ne was challenged. Although one maxillofacial surgeon 
conducted all the surgeries, creating the same accurate 
condition for all the patients, including surgery duration, 
trauma imposed on the surgery site, fracture type and 
other psychological factors, was not possible, which mi-
ght have influenced the results of the study. 
On the other hand, it was not possible to blind the pa-
tients to the study because some of them received spray 
and some received injection. Another limitation of this 
study was the small sample size. It is suggested that lar-
ger sample sizes be used in future studies. Simultaneous 
use of oral or injected acetaminophen with intranasal 
ketorolac to manage acute pain in the first 6 hours after 
surgery is another suggestion that can be considered in 
future studies. In addition, in this study, only intrave-
nous injection was used while other studies believe that 
intramuscular injection is more effective. 
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